English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/113013
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Autoradiographic distribution of M1, M2, M3, and m4 muscarinic receptor subtypes in Alzheimer's disease

AuthorsRodríguez-Puertas, Rafael; Pascual, Julio; Vilaró, Maria Teresa CSIC ORCID; Pazos, Ángel CSIC ORCID
KeywordsM2 muscarinic receptors
M1 muscarinic receptors
muscarinic receptors
M3 muscarinic receptors
M4 muscarinic receptors
quantitative receptor autoradiography
Alzheimer's disease
Issue DateAug-1997
PublisherJohn Wiley & Sons
CitationSynapse 26(4): 341-350 (1997)
AbstractWe studied the autoradiographic densities of all pharmacologically characterized muscarinic receptors (MR) in frontal, temporal, and visual cortex, hippocampal formation, and striatum in autopsied brains from 19 histopathologically verified patients of Alzheimer's disease (AD) and in matched controls. Almost all (16 of 19) of the AD cases were severe. In AD brains, total MR, M1, and M3 MR subtypes were found to be significantly decreased in entorhinal cortex and in most hippocampal strata. Total MR and M1 receptors were also significantly reduced in visual area and in frontal cortex of AD brains, respectively. M2 receptors were significantly reduced over hippocampal formation but increased significantly in striatum of AD brains as compared with controls. M3 receptors in AD were in the range of controls in neocortex and striatum, whereas the M4 receptor subtype was also preserved in all brain regions in AD brains when compared with controls. This is the first autoradiographic study analysing the distribution of all MR subtypes in AD brains. These changes in MR densities concur with the general pattern of neuronal degeneration occurring in AD brains and partly explain the poor response of AD cognitive decline to present cholinergic supplementation therapies. Although M3 and M4 MR were labelled with nonselective approaches, the preservation of M4 and to a lesser degree M3 MR subtypes in AD brains could open an alternative way for the symptomatic therapy of AD dementia.
Publisher version (URL)http://dx.doi.org/10.1002/(SICI)1098-2396(199708)26:4<341::AID-SYN2>3.0.CO;2-6
Identifiersdoi: 10.1002/(SICI)1098-2396(199708)26:4<341::AID-SYN2>3.0.CO;2-6
issn: 0887-4476
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.